Get started

Stockstobuy

Good-Buy STOCKS: HOODHi Traders, Investors and Speculators of Charts📈📉 After losing nearly 90% of it's high, NASDAQ:HOOD is currently trading close to all-time lows. This could make for a great buy and hold opportunity, whilst some patience may be needed to wait for ideal target zones. Higher lows are observed after bottoming out at $6, indicating that the bottom is most likely in for HOOD. In other words a spot entry here has a really low risk and high reward setup. _______________________ 📢Follow us here on TradingView for daily updates and trade ideas on crypto , stocks and commodities 💎Hit like & Follow 👍 We thank you for your support ! CryptoCheck NASDAQ:HOOD
NASDAQ:HOODLong
by CryptoCheck-
9
SRPT Sarepta Therapeutics Potential Buyout SoonIf you haven`t bought SRPT here: Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November. This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some even bought the $210 strike price! They also have a big partnership with the giant Roche Holding AG (RHHBY). I think SRPT Sarepta Therapeutics is well positioned for a potential takeover soon! Looking forward to read your opinion about it.
NASDAQ:SRPTLong
by TopgOptions
ACRS Aclaris Therapeutics Potential BuyoutACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025. ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023. ACRS reached 52 week low today: $5.05. Analysts Price Targets: $21 The Goldman Sachs Group $29 BTIG Research $38 Cantor Fitzgerald $43 HC Wainwright Considering the above, I think ACRS might be an easy +3X! Looking forward to read your opinion about it.
NASDAQ:ACRSLong
by TopgOptions
3
Naga Dhunseri Mid Term Idea with an RR of 1:5, 50% + ROI1) The stock is poised for a multiyear breakout, it has formed an ascending triangle pattern in monthly timeframe indicating a strong up move once after the ATH is broken. 2) Candlesticks show extremely bullish price action. Inside bars in Monthly as well. 3) RSI in monthly and weekly are supportive, moving up after a small correction. For a swing trade - One can enter at the demand 1 level if there is a reversal in hourly / 75 min time frame and look for Target 1 and Target 2 zones as targets. 10% up move. For a mid term trade - One can look to enter at the same demand zone as swing, or once after the ATH is sold off at first and then at a further upside reversal, precisely after a dip and bounce back in Daily timeframe RSI as currently it is inching 90+. As per risk management. For the Mid term, SL can be at 1500. Targets at 3100. Wish you all profits and happy trading!
NSE:NDGLLong
by Rugminik
1
NVAX Novavax Vaccine approved! Buy Opportunity!If you haven`t bought NVAX during the pandemic: Then you need to know that NVAX Novavax's recent achievements in gaining full marketing authorization for its COVID-19 vaccine, Nuvaxovid, in the UK and Singapore, alongside its availability in major U.S. pharmacies, have ignited optimism among investors. These milestones signify a bright future for NVAT stock. The international authorization of Nuvaxovid opens doors to vast markets, enhancing revenue potential and global recognition for Novavax. the EU delayed the approval, but will update its decision by the end of this month. Nuvaxovid's availability at CVS and Rite Aid in the U.S. immediately after regulatory clearance demonstrates its acceptance and accessibility. Nuvaxovid is a protein-based COVID-19 vaccine, different from the mRNA vaccines of PFE and MRNA. My price target is $10 by the end of this month. Looking forward to read your opinion about it.
NASDAQ:NVAXLong
by TopgOptions
LYFT in a bearish channel.LYFT Inc - 30d expiry - We look to Sell at 11.99 (stop at 12.91) Trading within a Bearish Channel formation. The sequence for trading is lower lows and highs. The primary trend remains bearish. Preferred trade is to sell into rallies. The trend of lower highs is located at 12.00. Our profit targets will be 9.81 and 9.41 Resistance: 11.53 / 12.00 / 12.45 Support: 10.75 / 10.30 / 9.72 Please be advised that the in formation presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group
NASDAQ:LYFTShort
by VantageMarkets